Bioventus, Inc. (BVS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$10.68-6.48%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · BVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.5% |
| Our one-year growth estimate | diamond | 7.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 35.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 28 industry peers · Company calendar date is not available
BVS — earnings in line
Dated 2026-11-02
Results of Operations and Financial Condition. On November 2, 2026, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 26, 2026 . A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…
Why it matters: Cash funded $42 million of debt payments in the first half. Meeting the cash goal can support more debt reduction.
Supportive ifFull-year cash from operations reaches at least $84 million.
Worry ifFull-year cash from operations falls below $84 million. Or, the company lowers its $84 million to $89 million range.
Why it matters: Pain Treatments led Q2 growth, with strong Durolane volume. A sharp slowdown would weaken this growth driver.
Supportive ifPain Treatments revenue grows at least 10% year over year in the next reported quarter.
Worry ifPain Treatments revenue grows less than 5% year over year or falls from a year ago.
Why it matters: The company kept its 2026 sales range at $600 million to $610 million. Results below the range would weaken that outlook.
Supportive ifFull-year 2026 net sales land at or above $600 million.
Worry ifFull-year 2026 net sales fall below $600 million, or the company cuts its sales range.
Why it matters: The board is weighing a sale and other paths. A signed deal would resolve a key open question.
Watch forThe company announces a signed sale deal with stated terms.
Also watch forThe board ends the review with no deal and confirms the company will stay independent.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$213 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $416 loss on $10,000 · 4.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,824 loss on $10,000 · 28.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.